This is a working overview of peptide analog, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-07 and is reviewed periodically as new material appears.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
== Development and regulation in the United States == The solid filiform needle used in dry needling is regulated by the FDA as a Class II medical device described in the code titled "Sec. 880.5580 Acupuncture needle is a device intended to pierce the skin in the practice of acupuncture". Per the Food and Drug Act of 1906 and the subsequent amendments to said act, the FDA definition applies to how the needles can be marketed and does not mean that acupuncture is the only medical procedure where these needles can be used. Dry needling using such a needle contrasts with the use of a hollow hypodermic needle to inject substances such as saline solution, botox or corticosteroids to the same point. The founder of Integrative Systemic Dry Needling (ISDN), Yun-Tao Ma, has spearheaded the "dry needling" movement in the United States. Ma states, "Although ISDN originated in traditional Chinese methods, it has developed from the ancient empirical approach to become modern medical art rooted in evidence-based thinking and practice." Ma also states that, "Dry needling technique is a modern Western medical modality that is not related to traditional Chinese acupuncture in any way. Dry needling has its own theoretical concepts, terminology, needling technique, and clinical application."
== Forums == Bodybuilding.com once had the most popular Internet forums dedicated to fitness discussion. After its closure, Aftermath's Chris Person wrote that in the history of forums, it "was so gargantuan it barely needs mentioning". As of 2022, 18 million people used them, making them one of the last remaining, popular Web 1.0 forums. They were known for having a large amount of trolling; a politically diverse userbase (notable in comparison to other forums like right-wing 4chan); and expansive discussion of subjects unrelated to fitness, in the Misc. (miscellaneous) subforum. Users of the subforum were known as "Miscers". In health-related posts, users often logged their workouts, signed up for bodybuilding challenges made by others, reviewed supplements, and gave others motivational support. Notable users included WWE wrestler Lars Sullivan; bodybuilder Zyzz (who died of cardiac arrest in 2011, possibly from anabolic steroid use); and Elliot Rodger, the perpetrator of the 2014 Isla Vista killings. In 2014, the forums popularized the word "nutting" as slang for ejaculation. The forums were involved in many controversies. In 2008, a man named Abraham Biggs died of suicide after being bullied on the site. He livestreamed his suicide on Justin.tv, and posted a link to the stream on the forums beforehand. In 2011, user ThePoz discovered an exploit that allowed anyone to access private photographs of Facebook CEO Mark Zuckerberg on the Facebook site itself, then publicized the method on the forums.
== Sources == Cox H (2000). The Global Cigarette: Origins and Evolution of British American Tobacco, 1880-1945. Oxford University Press. ISBN 978-0-19-829221-0. "E-Cigarette Use Among Youth and Young Adults: A Report of the Surgeon General" (PDF). United States Department of Health and Human Services. Surgeon General of the United States. 2016. pp. 1–298. Archived (PDF) from the original on October 9, 2022. This article incorporates text from this source, which is in the public domain. "Electronic nicotine delivery systems" (PDF). World Health Organization. July 21, 2014. pp. 1–13. Wilder N, Daley C, Sugarman J, Partridge J (April 2016). "Nicotine without smoke: Tobacco harm reduction". Royal College of Physicians. UK. pp. 1–191. Archived from the original on May 5, 2016. Retrieved June 2, 2019.
Sources: en.wikipedia.org
== PDI-PIXE-MS == Particle desorption ionisation particle-induced X-ray emission mass spectrometry (PIXE-MS) is a technique which combines PIXE with mass spectrometry of molecules. Elemental determinations are performed by PIXE with a heavy ion, such as oxygen, while simultaneously collecting the molecular ions for mass analysis in a quadrupole mass spectrometer, or time-of-flight (TOF) instrument. ICP-MS only determines elemental constituents using mass spectrometry, not molecular information. Sequential scanning may be done with a hydrogen ion beam and then a heavy ion beam to desorb and ionise the analyte sample. This technique allows for the analysis of both the elemental constituents as well as the molecular ions, or molecular speciation, present in a sample, using a heavy ion beam. This makes use, typically, of a 4 MeV accelerator with samples prepared in glycerol, on carbon felt.
== Services == Among the services provided by F2 Logistics include warehousing, cold chain distribution, ISO tank solutions, customs brokerage, and oversized cargo movement. The company also provide international freight forwarding through its network of partner sea and airfreight firms. F2 Logistics deals with the transport of retail goods such as food items to supermarkets, fast food outlets, and other retail outlets as well as medicine to drugstores.
cocovenenans is commonly found in plants and soil, which can be taken up by coconuts and corn, leading to the synthesis of bongkrek acid during the fermentation of such foods. Since 1975, consumption of contaminated tempe bongkrek has caused more than 3000 cases of bongkrek acid poisoning. In Indonesia, the overall reported mortality rate has turned out to be 60%. Due to the severity of the situation, the production of tempe bongkrek has been banned since 1988. Clandestine manufacture continues, however, due to the popular flavor. The problem of contamination is not encountered with bean and grain tempeh, which have a different composition of fatty acids that is not favorable for the growth of B. gladioli, but encourages growth of Rhizopus instead. When bean or grain tempeh has the proper color, texture and smell, it is a very strong indication the product is safe. Yellow tempe bongkrèk is always highly toxic due to toxoflavin, but tempe bongkrèk with a normal coloration may still contain lethal amounts of bongkrek acid.
The Japanese Black (黒毛和種, kuroge washu), which constitutes over 97% of beef cattle in Japan; regional strains within the breed include the Tottori, Tajima, Shimane and Okayama. The Japanese Brown or Japanese Red (褐毛和種, akage washu or akaushi), the other main breed, representing about 5% of all beef cattle; reared in southern Japan, in Kōchi Prefecture on Shikoku island, and in Kumamoto Prefecture on Kyushu island. The Japanese Polled (無角和種, mukaku washu), found principally in Yamaguchi Prefecture The Japanese Shorthorn (日本短角和種, nihon tankaku washu), reared in northern Japan, mainly in Iwate Prefecture; it constitutes less than one percent of all wagyu cattle.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.